{"id":433,"date":"2020-12-26T13:50:32","date_gmt":"2020-12-26T21:50:32","guid":{"rendered":"http:\/\/leadinglifetechnologies.com\/?page_id=433"},"modified":"2026-06-08T13:14:54","modified_gmt":"2026-06-08T20:14:54","slug":"peg-allergy-literature","status":"publish","type":"page","link":"https:\/\/leadinglifetechnologies.com\/?page_id=433","title":{"rendered":"Literature"},"content":{"rendered":"\n

(362 publications updated 2026-06-08)<\/strong><\/p>\n\n\n\n

Inflammatory and immune-mediated toxicity of lipid nanoparticles (2026<\/strong>).<\/a><\/p>\n\n\n\n

Overview of allergic disease: Anaphylaxis \u2013WAO White Book on Allergy 2026 \u2013 2.11 (2026<\/strong>).<\/a><\/p>\n\n\n\n

Pre-existing anti-polyethylene glycolantibodies in pregnant women and newborns (2026<\/strong>).<\/a><\/p>\n\n\n\n

Severe Allergic Drug Reaction to Ultrasound Enhancing Agent Resulting in Cardiogenic Shock (2026<\/strong>).<\/a><\/p>\n\n\n\n

AFM-Based Single-Molecule Force Spectroscopy of PEG\u2212Anti-PEG Antibody Interactions (2026<\/strong>).<\/a><\/p>\n\n\n\n

Effectiveness and safety of pegylated filgrastim (Pelgraz\u00ae) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany (2026<\/strong>).<\/a><\/p>\n\n\n\n

Editorial: Anaphylaxis challenges: idiopathic and rare causes (2026<\/strong>).<\/a><\/p>\n\n\n\n

Cardiac Arrest From Sulfur Hexafluoride Contrast Anaphylaxis After Prior Perflutren Hypersensitivity (2026<\/strong>).<\/a><\/p>\n\n\n\n

CDC Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2024-2025 Formulation) (2026<\/strong>).<\/a><\/p>\n\n\n\n

Prick tests and basophil activation tests in hypersensitivity to SARS-CoV-2 vaccines and components (2026<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol: A hidden allergy risk? (2026<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Allergy to Polyethylene Glycols. Anaphylaxis UK factsheet (2025<\/strong>)<\/a>.<\/p>\n\n\n\n

Allergological evaluation of hypersensitivity reactions after administration
of contrast agents: What the radiologist needs to know (2025<\/strong>).<\/a><\/p>\n\n\n\n

PEGylated Proteins: How Much Does Molecular Weight Matter? (2025<\/strong>).<\/a><\/p>\n\n\n\n

The Ubiquitous Use of Polyethylene Glycol in Pharmaceutical Design and Development: Technological Aspects and Future Perspectives (2025<\/strong>).<\/a><\/p>\n\n\n\n

Immunological Considerations of Polysorbate as an Excipient in Botulinum Neurotoxin Type A Formulations: A Narrative Review (2025<\/strong>).<\/a><\/p>\n\n\n\n

Evaluation of Plasma Polyethylene Glycol (PEG) Levels in a Healthy Adult Population (2025<\/strong>).<\/a><\/p>\n\n\n\n

Quality assurance and control – test results of COVID-19 mRNA vaccines from Pfizer and Moderna (2025<\/strong>).<\/a><\/p>\n\n\n\n

Contemporary Safety of Ultraso und Enhancing Agents in a Nationwide Analysis (2025<\/strong>).<\/a><\/p>\n\n\n\n

Development of a screening checklist to identify individuals with suspected allergy to polyethylene glycol (2025<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 Vaccines: Tolerance of Vaccination in Patients with Allergies (2025<\/strong>).<\/a><\/p>\n\n\n\n

Safety of Ultrasound- Enhancing Agents: Gazing Backward While Looking Forward (2025<\/strong>).<\/a><\/p>\n\n\n\n

Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform (2025<\/strong>).<\/a><\/p>\n\n\n\n

Basophil activation test to BNT162b2 lacks specificity for predicting allergic reactions to the mRNA vaccine (2025<\/strong>).<\/a><\/p>\n\n\n\n

Comparative immunologic profiling of mRNA and protein-conjugated vaccines: acute inflammatory responses and anti-PEG antibody production (2025<\/strong>).<\/a><\/p>\n\n\n\n

Detection of PEG-specific antibodies in SARS-CoV-2 positive and negative sera with implications for autoimmune reactivity (2025<\/strong>).<\/a><\/p>\n\n\n\n

Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial (2025<\/strong>).<\/a><\/p>\n\n\n\n

Perflutren lipid microspheres for echocardiogram contrast: a clinical case of anaphylaxis not caused by PEG (2025<\/strong>).<\/a><\/p>\n\n\n\n

Comment on \u201cAdverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review\u201d (2025<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol (PEG)-Induced Anaphylaxis: A Cautionary Case for the Gastroenterologist in the COVID Era (2025<\/strong>).<\/a><\/p>\n\n\n\n

Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign (2025<\/strong>).<\/a><\/p>\n\n\n\n

Challenges in diagnosing polyethylene glycol and polysorbate 80 allergies: implications for allergic reactions in COVID-19 mRNA vaccination program: experience from Qatar (2025<\/strong>).<\/a><\/p>\n\n\n\n

Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization (2025<\/strong>).<\/a><\/p>\n\n\n\n

Excipients in pharmaceuticals: mechanisms of hypersensitivity and the role of global pharmacovigilance (2025<\/strong>).<\/a><\/p>\n\n\n\n

Considering the immunogenicity of PEG: strategies for overcoming issues with PEGylated nanomedicines (2025<\/strong>).<\/a><\/p>\n\n\n\n

PEGylation technology: addressing concerns, moving forward (2025<\/strong>).<\/a><\/p>\n\n\n\n

Implications of Anaphylaxis Following mRNA-LNP Vaccines: It Is Urgent to Eliminate PEG and Find Alternatives (2025<\/strong>).<\/a><\/p>\n\n\n\n

A Shocking Contrast: Anaphylaxis Following Lumason Injection (2025<\/strong>).<\/a><\/p>\n\n\n\n

Diagnosis of Hypersensitivity to Components of Anti-COVID Vaccines. JACI Abstract. (2025<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 mRNA vaccine allergy. Review. (2025<\/strong>).<\/a><\/p>\n\n\n\n

Serious adverse events associated with bowel preparation for colonoscopy in Japan: Systematic review (2025<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Impact of Pre-existing Anti-polyethylene Glycol Antibodies on the Pharmacokinetics and Efficacy of a COVID-19 mRNA Vaccine (Comirnaty) In Vivo (2024<\/strong>).<\/a><\/p>\n\n\n\n

Elucidating allergic reaction mechanisms in response to SARS- CoV- 2 mRNA vaccination in adults (2024<\/strong>).<\/a><\/p>\n\n\n\n

Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice. Abstract (2024<\/strong>).<\/a><\/p>\n\n\n\n

Optimizing Pharmacological and Immunological Properties of Therapeutic Proteins Through PEGylation: Investigating Key Parameters and Their Impact (2024<\/strong>).<\/a><\/p>\n\n\n\n

Perspectives on complement and phagocytic cell responses to nanoparticles: From fundamentals to adverse reactions (2024<\/strong>).<\/a><\/p>\n\n\n\n

mRNA-LNPCOVID-19VaccineLipids Induce Complement Activation and Production of Proinflammatory Cytokines: Mechanisms, Effects of Complement Inhibitors, and Relevance to Adverse Reactions (2024<\/strong>).<\/a><\/p>\n\n\n\n

The Role of the Basophil Activation Test in the Diagnosis of Drug-Induced Anaphylaxis (2024<\/strong>).<\/a><\/p>\n\n\n\n

Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial (2024<\/strong>).<\/a><\/p>\n\n\n\n

Optimized ELISA for Anti-PEG Antibody Detection in Healthy Donors and Patients Treated with PEGylated Liposomal Doxorubicin (2024<\/strong>).<\/a><\/p>\n\n\n\n

Pegvaliase for the treatment of phenylketonuria: Final results of a long-term phase 3 clinical trial program (2024).<\/strong><\/a><\/p>\n\n\n\n

Pegvaliase-induced immediate hypersensitivity reaction after the discontinuation of antihistamine therapy in a patient with phenylketonuria \u2013 Case report (2024<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactoid reactions during implantation of polymer-filled ring stent grafts for treatment of abdominal aortic aneurysms (2024<\/strong>).<\/a><\/p>\n\n\n\n

Antigenicity Extension: A Novel Concept Explained by the Immunogenicity of PEG (2024<\/strong>).<\/a><\/p>\n\n\n\n

Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy (2024<\/strong>).<\/a><\/p>\n\n\n\n

Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study (2024<\/strong>).<\/a><\/p>\n\n\n\n

Allergy to PEG (polyethylene glycol) \u2013 sensitivity of basophil activation test with COVID-19 mRNA-vaccine BNT162B2 (2024<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis after SonoVue: A Case Report and a Literature Review (2024<\/strong>).<\/a><\/p>\n\n\n\n

Regulating Immune Responses Induced by PEGylated Messenger RNA\u2013Lipid Nanoparticle Vaccine (2024<\/strong>).<\/a><\/p>\n\n\n\n

Incidence and management of the main serious adverse events reported after COVID- 19 vaccination (2024<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic shock and cardiac arrest after intravenous injection of sulphur hexafluoride SonoVue (2024<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 mRNA Vaccination Appears Safe in Pediatric Patients With Hypersensitivity To PEGylated Escherichia Coli L Asparaginase (2024<\/strong>).<\/a><\/p>\n\n\n\n

Feasibility of a drug allergy registry-based excipient allergy database and call for universal mandatory drug ingredient disclosure: the case of PEG (2024<\/strong>).<\/a><\/p>\n\n\n\n

Development of anti-PEG IgG\/IgM\/IgE ELISA assays for profiling anti-PEG immunoglobulin response in PEG-sensitized individuals and patients with alpha-gal allergy (2024<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol Hypersensitivity: A Diagnostic and Management Dilemma (2024<\/strong>).<\/a><\/p>\n\n\n\n

Rare causes of pediatric anaphylaxis due to obscure allergens (2024<\/strong>).<\/a><\/p>\n\n\n\n

The role of skin tests with polyethylene glycol and polysorbate 80 in the vacciation campaign for COVID-19: results from an Italian multicenter survey (2024<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis after treatment with an endodontic material containing polyethylene glycol (2024<\/strong>).<\/a><\/p>\n\n\n\n

Anti-poly(ethylene glycol) (PEG) antibodies: from where are we coming and where are we going (2024<\/strong>).<\/a><\/p>\n\n\n\n

PEGylated liposomes for diagnosis of polyethylene glycol allergy (2024<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19vaccines: anaphylaxis and anxiety—A case study from an allergy unit (2024<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study (2024<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol allergy \u2026 for real this time! (2024<\/strong>).<\/a><\/p>\n\n\n\n

A randomized double-blinded trial to assess recurrence of systemic allergic reactions following COVID-19 mRNA vaccination (2024<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis Associated with Calaspargase in Pediatric Patients with Acute Lymphoblastic Leukemia. Abstract (2024<\/strong>).<\/a><\/p>\n\n\n\n

Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review (2024<\/strong>).<\/a><\/p>\n\n\n\n

A case of anaphylaxis to cardiac ultrasound enhancing agent (2024<\/strong>).<\/a><\/p>\n\n\n\n

Verdict of medical misadventure in case of fatal allergic reaction \u2013 The Irish Times<\/a> (2024<\/strong>).<\/p>\n\n\n\n

Anaphylactic shock during SpaceOAR Vue hydrogel procedure (2024<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

The COVID-19 mRNA vaccine Comirnaty induces anaphylactic shock in an anti-PEG hyperimmune large animal model (2023<\/strong>).<\/a><\/p>\n\n\n\n

An injectable PEG-like conjugate forms a subcutaneous depot and enables sustained delivery of a peptide drug (2023<\/strong>).<\/a><\/p>\n\n\n\n

Safety Profile of Ultrasound Enhancing Agents in Echocardiography Across Yale New Haven Health System (YNHHS) (2023<\/strong>).<\/a><\/p>\n\n\n\n

Safety Analysis of Adverse Events of Ultrasound Contrast Agent Lumason\/SonoVue in 49,100 Patients. Abstract (2023<\/strong>).<\/a><\/p>\n\n\n\n

Knife\u2019s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines (2023<\/strong>).<\/a><\/p>\n\n\n\n

mRNAlipid nanoparticles induce immune tolerance to treat human diseases (2023<\/strong>).<\/a><\/p>\n\n\n\n

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol (2023<\/strong>).<\/a><\/p>\n\n\n\n

Vaccination approach in patients with an allergic reaction to COVID-19 vaccines or at risk of developing allergic reactions (2023<\/strong>).<\/a><\/p>\n\n\n\n

Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System (2023<\/strong>).<\/a><\/p>\n\n\n\n

PEGylated therapeutics in the clinic (2023<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol\/polysorbate skin testing can be useful in risk assessment and management of allergic\/pseudoal lergic reactions to nanolipid\/adenoviral vaccines (2023<\/strong>).<\/a><\/p>\n\n\n\n

Reply to \u2018\u2018Polyethylene glycol\/polysor bate skin testing can be useful in risk assessment and management of allergic\/pseudoallergic reactions to nanolipid\/adenoviral vaccines\u2019\u2019 (2023<\/strong>).<\/a><\/p>\n\n\n\n

SARS-CoV-2 and allergy \u2013 what have we learned after two and a half years? (2023<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic Reactions to COVID-19 Vaccines: An Updated Assessment Based on Pharmacovigilance Data (2023<\/strong>)<\/a><\/p>\n\n\n\n

Anaphylaxis to Lumason Contrast agent in Echocardiography after Immune Sensitization: A Case Report and Literature Review (2023<\/strong>).<\/a><\/p>\n\n\n\n

PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective (2023<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic reactions after COVID-19 vaccination in Germany (2023<\/strong>).<\/a><\/p>\n\n\n\n

mRNA COVID\u201119 Vaccine Anaphylaxis: Epidemiology, Risk Factors, and Evaluation (2023<\/strong>).<\/a><\/p>\n\n\n\n

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG (2023<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines (2023<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylatoxin Complement 5a in Pfizer BNT162b2-Induced Immediate-Type Vaccine Hypersensitivity Reactions (2023<\/strong>).<\/a><\/p>\n\n\n\n

Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds (2023<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccine allergy advice and guidance: The experience of a UK tertiary referral centre (2023<\/strong>).<\/a><\/p>\n\n\n\n

Updated Guidance Regarding The Risk ofAllergic Reactions to COVID-19 Vaccines and Recommended Evaluation and Management: A GRADE Assessment, and International Consensus Approach (2023<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients (2023<\/strong>).<\/a><\/p>\n\n\n\n

Patients with polyethylene glycol allergy can experience immediate- type hypersensitivity reactions after exposure to analog substances (2023<\/strong>).<\/a><\/p>\n\n\n\n

Skin Testing and Basophil Activation Testing Is Useful for Assessing Immediate Reactions to Polyethylene Glycol-Containing Vaccines (2023<\/strong>).<\/a><\/p>\n\n\n\n

Anti\u2010polyethylene glycol (PEG) antibody isotypes may predict PEG\u2010associated allergy and COVID\u201019 protection among patients with history of suspected COVID\u201019 vaccine allergy (2023<\/strong>).<\/a><\/p>\n\n\n\n

Anti-PEG antibodies before and after a first dose of Comirnaty\u00ae (mRNA-LNP-based SARS-CoV-2 vaccine) (2023<\/strong>).<\/a><\/p>\n\n\n\n

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines (2023<\/strong>).<\/a><\/p>\n\n\n\n

Antibodies against Poly(ethyleneglycol) Activate Innate Immune Cells and Induce Hypersensitivity Reactions to PEGylated Nanomedicines (2023<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol (PEG) in mRNA-Based COVID-19 Vaccines: Impact, Immunogenicity, and its Potential Role in Post-Vaccination Induced Hypersensitivity (2023<\/strong>).<\/a><\/p>\n\n\n\n

Polythylene glycol severe allergy and SARS-CoV-2 vaccines: usefulness of testing with PEG 1500 extract (2023<\/strong>).<\/a><\/p>\n\n\n\n

Is polyethylene glycol allergy a real contraindication to COVID-19 mRNA vaccines? (2023<\/strong>).<\/a><\/p>\n\n\n\n

Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination (2023<\/strong>).<\/a><\/p>\n\n\n\n

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination (2023<\/strong>).<\/a><\/p>\n\n\n\n

Mast Cell Degranulation Links Anti-PEG IgE to Anaphylaxis Caused by PEGylated Drugs and PEG-contained LNP\/mRNA COVID Vaccines (2023<\/strong>).<\/a><\/p>\n\n\n\n

Endotyping of IgE-Mediated Polyethylene Glycol and\/or Polysorbate 80 Allergy (2023<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic shock induced by polyethylene glycol after bowel preparation for the colorectal cancer surgery: A case report (2023<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine (2022<\/strong>).<\/a><\/p>\n\n\n\n

Management of patients with immediate reactions to COVID-19 vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 in Europe: new challenges for addressing vaccine hesitancy (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis after COVID-19 vaccination: A registry-based study (2022<\/strong>).<\/a><\/p>\n\n\n\n

Outcomes of COVID- 19 vaccination in 323 patients with clonal and non- clonal mast cell activation disorders (2022<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccination in the setting of mastocytosis\u2014Pfizer-BioNTech mRNA vaccine is safe and well tolerated (2022<\/strong>).<\/a><\/p>\n\n\n\n

What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later (2022<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity Cross-Reactivity for Ultrasound-Enhancing Agents and COVID-19 Vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

Ultrasound-Enhancing Agents and Associated Adverse Reactions: A Potential Connection to the COVID-19 Vaccines? (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis and vertigo: 3 case reports (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis and skin reaction: 2 case reports (2022<\/strong>).<\/a><\/p>\n\n\n\n

Reporting of Allergic Reactions During Pfizer BioNTech BNTT162B2 Vaccination in Israel (2022<\/strong>).<\/a><\/p>\n\n\n\n

Monitoring Anti-PEG Antibodies Level upon Repeated Lipid Nanoparticle-Based COVID-19 Vaccine Administration (2022<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to the polyethylene glycol (PEG) excipients : 2 case reports (202<\/strong>2).<\/a><\/p>\n\n\n\n

Anaphylaxis to SARS\u2011CoV\u20112 Vaccines in the Setting of a Nationwide Passive Epidemiological Surveillance Program (2022<\/strong>).<\/a><\/p>\n\n\n\n

Safety of mRNA-based COVID-19 vaccination in pediatric patients with a PEG-asparaginase allergy (2022<\/strong>).<\/a><\/p>\n\n\n\n

COVID vaccination can be performed in patients with a history of allergic reactions to the vaccines or their components: experience from a specialist clinic in South Australia (2022<\/strong>).<\/a><\/p>\n\n\n\n

Allergic Reactions to COVID-19 Vaccination in High-Risk Allergic Patients: The Experience of Trieste University Hospital (North-Eastern Italy) (2022<\/strong>).<\/a><\/p>\n\n\n\n

Covid-19 vaccine reactions and suspected polyethylene glycol allergy: a pediatric case series (P010) (2022<\/strong>).<\/a><\/p>\n\n\n\n

Variability of eliciting thresholds in PEG allergy limits prediction of tolerance to PEG-containing mRNA COVID vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

The conundrum of COVID-19 mRNA vaccine induced anaphylaxis (2022<\/strong>).<\/a><\/p>\n\n\n\n

Successful mRNA COVID-19 Vaccination and Colonoscopy After Oral Desensitization in a Patient With Polyethylene Glycol Allergy (2022<\/strong>).<\/a><\/p>\n\n\n\n

Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies (2022<\/strong>).<\/a><\/p>\n\n\n\n

PEG allergy\u2014ACOVID-19 pandemic-made problem? A German perspective (2022<\/strong>).<\/a><\/p>\n\n\n\n

Basophil Activation Test with Different Polyethylene Glycols in Patients with Suspected PEG Hypersensitivity Reactions (2022<\/strong>).<\/a><\/p>\n\n\n\n

Patients with previous immediate hypersensitivity reactions to polyethylene glycol can safely receive the BNT162b2 mRNA COVID-19 vaccine (2022<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol allergy and immediate-type hypersensitivity reaction to COVID-19 vaccination: case report (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to Excipients in Current Clinical Practice: Evaluation and Management (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. Abstract. (2022<\/strong>).<\/a><\/p>\n\n\n\n

Serum polyethylene glycol-specific IgE and IgG in patients with hypersensitivity to COVID-19 mRNA vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies (2022<\/strong>).<\/a><\/p>\n\n\n\n

Adverse reactions to BNT162B2 vaccine in health care workers from an Italian Tertiary Care Hospital (2022<\/strong>).<\/a><\/p>\n\n\n\n

Allergic Reactions After the Administration of COVID-19 Vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

Allergies and COVID-19 vaccines: An ENDA\/EAACI Position paper (2022<\/strong>).<\/a><\/p>\n\n\n\n

Allergy evaluation of messenger RNA vaccine reactions is crucial, with a specific role for polyethylene glycol testing (2022)<\/strong>.<\/a><\/p>\n\n\n\n

Allergy to polyethylene glycol and polysorbates in a patient cohort: Diagnostic work\u2010up and decision points for vaccination during the COVID\u201019 pandemic (2022<\/strong>)<\/a>.<\/p>\n\n\n\n

Anaphylactic reactions to polyethylene glycol-containing bowel cleansing preparations after Moderna COVID-19 vaccination (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis and Related Events Post-COVID-19 Vaccination: A Systematic Review (2022)<\/strong>.<\/a><\/p>\n\n\n\n

Anaphylaxis caused by pegylated recombinant human granulocyte colony-stimulating factor (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to additives in vaccines (2022<\/strong>)<\/a><\/p>\n\n\n\n

Anti\u2011drug Antibody Validation Testing and Reporting Harmonization (2022<\/strong>).<\/a><\/p>\n\n\n\n

Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement (2022)<\/strong>.<\/a><\/p>\n\n\n\n

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

Complement Activation-Related Pseudo Allergy of PEGylated Products: Safety Aspects, Models, the Role of Anti-PEG Antibodies, and Ways to Overcome (2022<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccines and anaphylaxis\u2014evaluation with skin prick testing, basophil activation test and Immunoglobulin E (2022<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity Reactions to COVID-19 Vaccines\u2014 Identify High-risk Children and Vaccinate the Rest (2022<\/strong>).<\/a><\/p>\n\n\n\n

Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines Not the usual suspects? (2022<\/strong>).<\/a><\/p>\n\n\n\n

Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination (2022<\/strong>).<\/a><\/p>\n\n\n\n

mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulations (2022<\/strong>).<\/a><\/p>\n\n\n\n

mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase (2022<\/strong>).<\/a><\/p>\n\n\n\n

Non-allergic nature of vast majority of cutaneous adverse reactions to mRNA COVID-19 vaccines: implications on treatment and re-vaccination (2022<\/strong>).<\/a><\/p>\n\n\n\n

Oncologist counseling practice and COVID-19 vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity (2022)<\/strong>.<\/a><\/p>\n\n\n\n

Optimizing investigation of suspected allergy to polyethylene glycols (2022<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol and polysorbate testing in 12 patients before or after coronavirus disease 2019 vaccine administration (2022<\/strong>).<\/a><\/p>\n\n\n\n

Population-Based Incidence, Severity, and Risk Factors Associated with Treated Acute-Onset COVID-19 mRNA Vaccination-Associated Hypersensitivity Reactions (<\/a>2022).<\/a> <\/strong><\/p>\n\n\n\n

Potential culprits for immediate hypersensitivity reactions to BNT162b2 mRNA COVID-19 vaccine: not just PEG (2022<\/strong>).<\/a><\/p>\n\n\n\n

Rapid progress in our understanding of COVID-19 vaccine allergy: A cause for optimism, not hesitancy (2022<\/strong>).<\/a><\/p>\n\n\n\n

Risk, Causality and Management of Severe Allergic Reactions of RNA Messenger SARS-CoV-2 Vaccine: A Mini Review (2022<\/strong>).<\/a><\/p>\n\n\n\n

Successful mRNA COVID-19 vaccination in a patient with a history of severe polyethylene glycol anaphylaxis (2022<\/strong>).<\/a><\/p>\n\n\n\n

The adverse reactions to vaccines practice parameter 10 years on\u2014what have we learned? (2022<\/strong>). <\/a><\/p>\n\n\n\n

The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis (2022<\/strong>).<\/a><\/p>\n\n\n\n

The role of anti-polyethylene glycol (PEG) IgM, IgG, or IgE antibodies in COVID mRNA vaccine anaphylaxis is unknown. We highlight a case with preexisting anti-PEG antibodies that tolerated vaccination (2022<\/strong>)<\/a>.<\/p>\n\n\n\n

The safety of SARS-CoV-2 vaccines in persons with a known history of pegaspargase allergy: A single institution experience (2022<\/strong>).<\/a><\/p>\n\n\n\n

Ultrasound-Enhancing Agent Safety: Understanding the New Food and Drug Administration Warning on Polyethylene Glycol (2022).<\/strong><\/a><\/p>\n\n\n\n

Understanding the Role and Impact of Poly (Ethylene Glycol) (PEG) on Nanoparticle Formulation: Implications for COVID-19 Vaccines (2022<\/strong>).<\/a><\/p>\n\n\n\n

Ultrasound-Enhancing Agents and Associated Adverse Reactions: A Potential Connection to the COVID-19 Vaccines? (2022<\/strong>).<\/a><\/p>\n\n\n\n

Diagnostic accuracy of vaccine and vaccine excipient testing in the setting of allergic reactions to COVID- 19 vaccines: A systematic review and meta- analysis (2022<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of
PEGylated products (2022<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Surveillance for Adverse Events After COVID-19 mRNA Vaccination (2021<\/strong>).<\/a><\/p>\n\n\n\n

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US\u2014December 14, 2020-January 18, 2021 (2021<\/strong>).<\/a><\/p>\n\n\n\n

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose (2021<\/strong>).<\/a><\/p>\n\n\n\n

Safety of COVID-19 vaccination in patients with polyethylene glycol allergy: A case series (2021<\/strong>).<\/a><\/p>\n\n\n\n

Safety of administration of BNT162b2mRNA (Pfizer-BioNTech)COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase (2021<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis (2021<\/strong>).<\/a><\/p>\n\n\n\n

Contrast-enhanced ultrasound: a comprehensive review of safety in children (2021<\/strong>).<\/a><\/p>\n\n\n\n

Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Biphasic anaphylaxis after exposure to the first dose of Pfizer\u2010BioNTech COVID\u201019 mRNA vaccine (2021<\/strong>).<\/a><\/p>\n\n\n\n

mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis (2021<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer\/BioNTech mRNA COVID- 19 vaccine (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID- 19 vaccines tolerated in patients with paclitaxel and docetaxel allergy (2021<\/strong>).<\/a><\/p>\n\n\n\n

Utility and futility of skin testing to address concerns surrounding messenger RNA coronavirus disease 2019 vaccine reactions (2021<\/strong>).<\/a><\/p>\n\n\n\n

Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk (2021<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to vaccination and polyethylene glycol: a perspective from the European Anaphylaxis Registry (2021<\/strong>).<\/a><\/p>\n\n\n\n

Allergenic components of the mRNA- 1273 vaccine for COVID- 19: Possible involvement of polyethylene glycol and IgG- mediated complement activation (2021<\/strong>).<\/a><\/p>\n\n\n\n

Successful SARS-CoV-2 vaccine allergy risk management: The experience of a large Italian University Hospital (2021<\/strong>).<\/a><\/p>\n\n\n\n

Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions (2021<\/strong>).<\/a><\/p>\n\n\n\n

Patients with suspected allergic reactions to COVID\u201019 vaccines can be safely revaccinated after diagnostic work\u2010up (2021<\/strong>).<\/a><\/p>\n\n\n\n

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing (2021<\/strong>).<\/a><\/p>\n\n\n\n

An injectable excipient prevents anti-polyethylene glycol antibody mediated hypersensitivity (2021<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity to different polyethylene glycol containing products (2021<\/strong>).<\/a><\/p>\n\n\n\n

A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies (2021<\/strong>).<\/a><\/p>\n\n\n\n

Administration of the Comirnaty\u00ae Vaccine in a Fractional Regimen in Two Patients with Immediate Acute Urticaria after the First Dose (2021<\/strong>).<\/a><\/p>\n\n\n\n

Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy Northwell Health experience (2021<\/strong>).<\/a><\/p>\n\n\n\n

Allergic Reactions to COVID-19 Vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Adverse reactions to COVID-19 vaccines: A practical approach (2021<\/strong>).<\/a><\/p>\n\n\n\n

Allergic reactions to COVID-19 vaccinations\u2014unveiling the secret(s) (2021<\/strong>).<\/a><\/p>\n\n\n\n

Allergy to polyethylene glycol\/macrogol following dental surgery (2021<\/strong>).<\/a><\/p>\n\n\n\n

An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history (2021<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic reactions to novel mRNA SARS-CoV-2\/COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation (2021<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don’t give up on the second dose! (2021<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to Pfizer\/BioNTech mRNA COVID-19 Vaccine in a Patient With Clinically Confirmed PEG Allergy (2021<\/strong>).<\/a><\/p>\n\n\n\n

Answers to burning questions for clinical allergologists related to the new COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Assessment of Allergic and Anaphylactic Reactions to mRNA COVID-19 Vaccines With Confirmatory Testing in a US Regional Health System (2021<\/strong>).<\/a><\/p>\n\n\n\n

Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients (2021<\/strong>).<\/a><\/p>\n\n\n\n

Coronavirus disease 2019 vaccine administration in patients with reported reactions to polyethylene glycol- and polysorbate\u0002-containing therapeutics (2021<\/strong>)<\/a>.<\/p>\n\n\n\n

COVID-19 mRNA vaccine allergy (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 Vaccines in Children with Cow\u2019s Milk and Food Allergies (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccine-associated anaphylaxis: Astatement of the World Allergy OrganizationAnaphylaxis Committee (2021<\/strong>)<\/a>.<\/p>\n\n\n\n

COVID-19 vaccine anaphylaxis: IgE, complement or what else? A reply to: \u201cCOVID-19 vaccine anaphylaxis: PEG or not?\u201d (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccines and the role of other potential allergenic components different from PEG. A reply to: \u201cOther excipients than PEG might cause serious hypersensitivity reactions in COVID-19 vaccines\u201d (2021<\/strong><\/a>).<\/p>\n\n\n\n

COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria\/Angioedema\/Anaphylaxis Working Group (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccine testing & administration guidance for allergists\/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI) (2021<\/strong>).<\/a><\/p>\n\n\n\n

COVID-19 vaccines and vaccine hesitancy: Role of the allergist\/immunologist in promotion of vaccine acceptance (2021<\/strong>).<\/a><\/p>\n\n\n\n

Covid-19 Vaccine-Associated Anaphylaxis: Basophil Activation In A Specific Ige And Igg Negative Patient (2021<\/strong>).<\/a><\/p>\n\n\n\n

Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders? (2021<\/strong>).<\/a><\/p>\n\n\n\n

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs (2021)<\/strong>.<\/a><\/p>\n\n\n\n

EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Excipients as potential agents of anaphylaxis in vaccines: analyzing the formulations of the current authorized COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Experience with polyethylene glycol allergy-guided risk management for COVID-19 vaccine anaphylaxis (2021<\/strong>).<\/a><\/p>\n\n\n\n

Expert Consensus Statement from the American Society of Echocardiography on Hypersensitivity Reactions to Ultrasound Enhancing Agents in Patients with Allergy to Polyethylene Glycol (2021<\/strong>).<\/a><\/p>\n\n\n\n

Evaluation of Patients with Vaccine Allergies Prior to mRNA-Based COVID-19 Vaccination (2021<\/strong>).<\/a><\/p>\n\n\n\n

Flow cytometry analysis of anti-polyethylene glycol antibodies in human plasma (2021<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity to polyethylene glycol (PEG) (2021<\/strong>). <\/a><\/p>\n\n\n\n

Hypersensitivity to polyethylene glycol in adults and children: An emerging challenge (2021<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity to the Moderna COVID-19 vaccine caused by tromethamine: PEG is not always the culprit excipient (2021<\/strong>). <\/a><\/p>\n\n\n\n

IgE-mediated allergy to polyethylene glycol (PEG) as a cause of anaphylaxis to mRNA COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) Including a PEG-containing COVID-19 Vaccine Revealed by Intradermal Testing (2021<\/strong>).<\/a><\/p>\n\n\n\n

In vivo and in vitro testing with PEGylated nanoparticles (2021<\/strong>).<\/a><\/p>\n\n\n\n

Localized and generalized urticarial allergic dermatitis secondary to SARS-CoV-2 vaccination in a series of 6 patients (2021<\/strong>).<\/a><\/p>\n\n\n\n

Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

mRNA, Nanolipid Particles and PEG: A Triad Never Used in Clinical Vaccines is Going to Be Tested on Hundreds of Millions of People (2021<\/strong>).<\/a><\/p>\n\n\n\n

mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach (2021<\/strong>).<\/a><\/p>\n\n\n\n

Non\u2212immunoglobulin E-mediated allergy associated with Pfizer-BioNTech coronavirus disease 2019 vaccine excipient polyethylene glycol (2021<\/strong>).<\/a><\/p>\n\n\n\n

Omalizumab prevents anaphylactoid reactions to mRNA COVID-19 vaccine (2021<\/strong>).<\/a><\/p>\n\n\n\n

PEG\/Polysorbate Skin Testing Has No Utility in the Assessment of Suspected Allergic Reactions to SARS-CoV-2 Vaccines (2021).<\/a><\/p>\n\n\n\n

PEG skin testing for COVID-19 vaccine allergy (2021<\/strong>).<\/a><\/p>\n\n\n\n

Pfizer\u2019s vaccine raises allergy concerns (2021<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol Allergy Label: Not An Absolute Contraindication To Receiving An mRNA Covid-19 Vaccine (2021<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions Early report (2021<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies (2021<\/strong>).<\/a><\/p>\n\n\n\n

Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines\u2014Much ado about nothing? (2021<\/strong>).<\/a><\/p>\n\n\n\n

Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

Practical handling of allergic reactions to COVID-19 vaccines A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and \u00d6GAI (2021<\/strong>).<\/a><\/p>\n\n\n\n

Practical recommendations for the allergological risk assessment of the COVID-19 vaccination \u2013 a harmonized statement of allergy centers in Germany (2021<\/strong>).<\/a><\/p>\n\n\n\n

Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada (2021)<\/strong>.<\/a><\/p>\n\n\n\n

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination (2021<\/strong>).<\/a><\/p>\n\n\n\n

Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose (2021<\/strong>).<\/a><\/p>\n\n\n\n

SARS-CoV-2 Vaccination and Anaphylaxis: Recommendations of the French Allergy Community and the Montpellier World Health Organization Collaborating Center (2021)<\/strong>.<\/a><\/p>\n\n\n\n

Severe allergic reactions after COVID-19 vaccination with the Pfizer\/BioNTech vaccine in Great Britain and USA (2021<\/strong>).<\/a><\/p>\n\n\n\n

Severe allergic reactions to the COVID-19 vaccine \u2013 statement and practical consequences (2021<\/strong>).<\/a><\/p>\n\n\n\n

Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000 (2021<\/strong>).<\/a><\/p>\n\n\n\n

The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World (2021<\/strong>).<\/a><\/p>\n\n\n\n

The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID-19 vaccines (2021<\/strong>).<\/a><\/p>\n\n\n\n

The Polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients (2021<\/strong>). <\/a><\/p>\n\n\n\n

The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach (2021<\/strong>).<\/a><\/p>\n\n\n\n

The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID-19 vaccine (2021<\/strong>).<\/a><\/p>\n\n\n\n

Ultrasound contrast agent hypersensitivity in patients allergic to polyethylene glycol: position statement by the European Association of Cardiovascular Imaging (2021<\/strong>).<\/a><\/p>\n\n\n\n

Vaccine allergy: evidence to consider for COVID-19 vaccines (2021<\/strong>). <\/a><\/p>\n\n\n\n

Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives (2021<\/strong>).<\/a><\/p>\n\n\n\n

PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol (2021<\/strong>).<\/a><\/p>\n\n\n\n

Specific IgE toward polyethylene glycol (PEG) measured by ImmunoCAP (2021<\/strong>).<\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

A Case Report of Angioedema and Anaphylactic Shock Induced by Ingestion of Polyethylene Glycol (2020<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? (2020<\/strong>).<\/a><\/p>\n\n\n\n

Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients (2020<\/strong>).<\/a><\/p>\n\n\n\n

Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker (2020<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis to PEGylated Liposomal Echocardiogram Contrast in a Patient with IgE-Mediated Macrogol Allergy (2020<\/strong>).<\/a><\/p>\n\n\n\n

Immediate Hypersensitivity Reactions Caused by Drug Excipients: A Literature Review (2020<\/strong>).<\/a><\/p>\n\n\n\n

IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper (2020<\/strong>).<\/a><\/p>\n\n\n\n

Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? (2020<\/strong>).<\/a><\/p>\n\n\n\n

Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals (2020<\/strong>).<\/a><\/p>\n\n\n\n

Anti-PEG IgE In anaphylaxis associated with Polyethylene Glycol (2020<\/strong>).<\/a><\/p>\n\n\n\n

Maintaining Safety with SARS-CoV-2 Vaccines (2020<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene glycol-induced systemic allergic reactions (anaphylaxis) (2020<\/strong>).<\/a><\/p>\n\n\n\n

Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions (2020<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge (2019<\/strong>).<\/a><\/p>\n\n\n\n

Immune\u2010mediated adverse reactions to vaccines (2019<\/strong>).<\/a><\/p>\n\n\n\n

FDA Guidance for Industry: Immunogenicity Testing of Therapeutic Protein Products \u2014 Developing and Validating Assays for Anti-Drug Antibody Detection (2019<\/strong>).<\/a><\/p>\n\n\n\n

Hypersensitivity to Polyethylene Glycols & Polysorbates (2019<\/strong>).<\/a><\/p>\n\n\n\n

Immediate Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We Have Recognized (2019)<\/strong>.<\/a><\/p>\n\n\n\n

Immediate hypersensitivity to polyethylene glycols in unrelated products: when standardization in the nomenclature of the components of drugs, cosmetics, and food becomes necessary (2019<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol Is a Cause of IgE-Mediated anaphylaxis (2019<\/strong>)<\/a>.<\/p>\n\n\n\n

Polyethylene glycols and polysorbates: Two still neglected ingredients causing true IgE-mediated reactions (2019<\/strong>)<\/a>.<\/p>\n\n\n\n

Pseudo-anaphylaxis to Polyethylene Glycol (PEG)-Coated Liposomes: Roles of Anti-PEG IgM and Complement Activation in a Porcine Model of Human Infusion Reactions (2019<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic shock secondary to the use of macrogol 4000 as a bowel cleanser : a case report (2019<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylaxis due to macrogol in a laxative solution with a positive basophil activation test (2019<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro (2018<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol Electrolyte Solution: Safety Considerations in Atopic Patients (2018<\/strong>)<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Outcome of pediatric patients with acute lymphoblastic eukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children’s Oncology Group (2017<\/strong>).<\/a><\/p>\n\n\n\n

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout (2017<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic Shock Due to Allergy to Macrogol 4000 Contained in SonoVue\u00ae (2017<\/strong>).<\/a><\/p>\n\n\n\n

Optimization of a PEGylated glucuronide monomethylauristatin E Linker for Antibody\u2013Drug Conjugates (2017<\/strong>).<\/a><\/p>\n\n\n\n

Three cases of anaphylaxis following injection of a depot corticosteroid with evidence of IgE sensitization to macrogols rather than the active steroid (2017<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

International Consensus (ICON): allergic reactions to vaccines (2016<\/strong>).<\/a><\/p>\n\n\n\n

Comparison of hypersensitivity rates to intravenous and intramuscular PEG asparaginase in children with acute lymphoblastic leukemia: Ameta-analysis and systematic review (2016<\/strong>).<\/a><\/p>\n\n\n\n

Contact Sensitization to Emulsifying Agents: An Underrated Issue? (2016<\/strong>).<\/a><\/p>\n\n\n\n

The Hidden Culprit: A Case of Repeated Anaphylaxis to Cremophor (2016<\/strong>).<\/a><\/p>\n\n\n\n

Analysis of pre-existing IgG and IgM antibodies against Polyethylene
Glycol (PEG) in the general population (2016<\/strong>).<\/a><\/p>\n\n\n\n

Allergic reactions associated with pegaspargase in adults (2016<\/strong>).<\/a><\/p>\n\n\n\n

Immediate-type hypersensitivity to polyethylene glycols: a review (2016)<\/strong>.<\/a><\/p>\n\n\n\n

Polyethylene glycol as a cause of anaphylaxis (2016<\/strong>).<\/a><\/p>\n\n\n\n

Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer (2016<\/strong>). <\/a><\/p>\n\n\n\n

Anaphylaxis following a transvaginal ultrasound (2016)<\/strong>. <\/a><\/p>\n\n\n\n

PEGylation of biopharmaceuticals: A review of chemistry and nonclinical safety information of approved drugs (2016<\/strong>). <\/a><\/p>\n\n\n\n

Anaphylaxis to Polyethylene Glycol (Colyte\u00ae) in a patient with diverticulitis (2016).<\/strong> <\/a><\/p>\n\n\n\n

Anti-PEG antibodies in the clinic: current issues and beyond PEGylation (2016<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Protracted anaphylaxis developed after peginterferon \u03b1-2a administration for chronic hepatitis C (2015<\/strong>).<\/a><\/p>\n\n\n\n

Multiple Drug Allergy Due to Hypersensitivity to Polyethylene Glycols of Various Molecular Weights (2015<\/strong>).<\/a><\/p>\n\n\n\n

Allergic reaction to polyethylene glycol in a painter (2015<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic shock caused by ingestion of<\/a> <\/a>Polyethylene Glycol (2015<\/strong>).<\/a><\/p>\n\n\n\n

Pre-existing anti\u2013polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer (<\/a>2015<\/strong>). <\/a><\/p>\n\n\n\n

Urticaria due to polyethylene glycol-3350 and electrolytes for oral solution in a patient with jejunal nodular lymphoid hyperplasia (2015<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycols (PEG) and related structures: overlooked allergens in the perioperative setting (2015<\/strong>).<\/a><\/p>\n\n\n\n

Polyethylene Glycol (PEG)-Induced Anaphylactic Reaction During Bowel Preparation (2015<\/strong>)<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients (2014<\/strong>).<\/a><\/p>\n\n\n\n

Potential induction of anti-PEG antibodies and complement activation
toward PEGylated therapeutics (2014<\/strong>).<\/a><\/p>\n\n\n\n

Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins (2014<\/strong>).<\/a><\/p>\n\n\n\n

Global atlas of allergy. Book in Chinese (2014<\/strong>). <\/a><\/p>\n\n\n\n

FDA Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products (2014<\/strong>).<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Inhibition of polyethylene glycol\u2013induced his\u0002tamine release by monomeric ethylene and diethylene glycol: A case of probable poly\u0002ethylene glycol allergy (2013<\/strong>)<\/a>. <\/p>\n\n\n\n

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety (2013<\/strong>).<\/a><\/p>\n\n\n\n

PEGylation of Biologics (2013<\/strong>)<\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80 (2012<\/strong>).<\/a><\/p>\n\n\n\n

A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid (2012<\/strong>). <\/a><\/p>\n\n\n\n

Positive skin test to pegylated drug in a patient with anaphylaxis to polyethylene glycol (2012<\/strong>).<\/a><\/p>\n\n\n\n

Pegylated interferon, but not conventional interferon therapy, induced severe skin lesions (2012).<\/strong> <\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Macrogol hypersensitivity in multiple drug allergy (2011<\/strong>).<\/a><\/p>\n\n\n\n

Product development issues for PEGylated proteins (review, 2011<\/strong>).<\/a><\/p>\n\n\n\n

Immunogenicity of Polyethylene Glycol (PEG). Review. (2011<\/strong>).<\/a><\/p>\n\n\n\n

A rare case of anaphylaxis to bowel Prep: A case report and review of the literature (2011)<\/strong>. <\/a><\/p>\n\n\n\n

********************************************************<\/p>\n\n\n\n

Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives (2010<\/strong>).<\/a><\/p>\n\n\n\n

PEGylated protein drugs: basic science and clinical applications. Book (2009<\/strong>).<\/p>\n\n\n\n

Immediate allergic reactions by polyethylene glycol 4000: two cases (2008<\/strong>).<\/a><\/p>\n\n\n\n

Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process (2008<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic shock after oral intake and contact urticaria due to polyethylene glycols (2007<\/strong>).<\/a><\/p>\n\n\n\n

Antibody against Poly(Ethylene Glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients (2007<\/strong>).<\/a><\/p>\n\n\n\n

Fatal aspiration of polyethylene glycol solution (2006<\/strong>)<\/a>.<\/p>\n\n\n\n

Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes (2006<\/strong>).<\/a><\/p>\n\n\n\n

Two cases of anaphylaxis to macrogol 6000 after ingestion of drug tablets (2006<\/strong>).<\/a><\/p>\n\n\n\n

Anaphylactic shock: pathophysiology, recognition, and treatment (2004)<\/strong>.<\/a><\/p>\n\n\n\n

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil\u00ae): possible role in hypersensitivity reactions (2003<\/strong>).<\/a><\/p>\n\n\n\n

Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies (2002<\/strong>)<\/a>.<\/p>\n\n\n\n

Urticarial reaction to oral polyethylene glycol electrolyte lavage solution (1992<\/strong>)<\/a>.<\/p>\n\n\n\n

Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors (1984<\/strong>)<\/a>.<\/p>\n\n\n\n

Anaphylaxis to polyethylene glycol (PEG) in a multivitamin tablet (1982<\/strong>)<\/a>.<\/p>\n\n\n\n

Immediate and delayed allergic contact reactions to polyethylene glycol (1978<\/strong>).<\/a><\/p>\n\n\n\n

<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

(362 publications updated 2026-06-08) Inflammatory and immune-mediated toxicity of lipid nanoparticles (2026). Overview of allergic disease: Anaphylaxis \u2013WAO White Book on Allergy 2026 \u2013 2.11 (2026). Pre-existing anti-polyethylene glycolantibodies in pregnant women and newborns (2026). Severe Allergic Drug Reaction to Ultrasound Enhancing Agent Resulting in Cardiogenic Shock (2026). AFM-Based Single-Molecule Force Spectroscopy of PEG\u2212Anti-PEG Antibody … <\/p>\n

Continue reading “Literature”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-433","page","type-page","status-publish","hentry"],"jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=\/wp\/v2\/pages\/433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=433"}],"version-history":[{"count":692,"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=\/wp\/v2\/pages\/433\/revisions"}],"predecessor-version":[{"id":4103,"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=\/wp\/v2\/pages\/433\/revisions\/4103"}],"wp:attachment":[{"href":"https:\/\/leadinglifetechnologies.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}